Amantadine hydrochloride ER is a Small Molecule owned by Adamas Pharmaceuticals, and is involved in 11 clinical trials, of which 10 were completed, and 1 is ongoing.

ADS-5102 (Nurelin, amantadine hydrochloride) acts as NMDA receptor antagonist. Amantadine causes greater amounts of dopamine to be released in the brain. It blocks receptors for acetylcholine, a brain chemical that contributes to control of movement. It acts on the pre-synaptic membrane, enhancing the release of dopamine and inhibiting its reuptake. Post-synaptically, amantadine acts directly on the dopamine receptor and up-regulates D2 receptors. Amantadine has antiglutamatergic properties, via non-competitive antagonism of NMDA receptors.

The revenue for Amantadine hydrochloride ER is expected to reach a total of $3.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Amantadine hydrochloride ER NPV Report.

Amantadine hydrochloride ER is currently owned by Adamas Pharmaceuticals. Supernus Pharmaceuticals is the other company associated in development or marketing of Amantadine hydrochloride ER.

Amantadine hydrochloride ER Overview

Amantadine hydrochloride (Gocovir, Nurelin and ADS-5102) is an adamantane derivative, acts as antiviral and antiparkinson agent. It is formulated as extended-release hard gelatin capsules for oral route of administration. Gocovir is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

ADS-5102 (Nurelin, amantadine hydrochloride ER) is under development for the treatment of walking impairment (gait abnormality) in multiple sclerosis patients and off episodes in Parkinson’s disease (PD) patients receiving levodopa-based therapy (dyskinesia). It was also under development for the treatment of Parkinson's disease, Tardive Dyskinesia, traumatic brain injury, weight gain and additional indications.

Supernus Pharmaceuticals Overview

Supernus Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; Trokendi XR (topiramate), an initial monotherapy in patients with partial-onset of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome; Apokyn, and Xadago for Parkinson’s disease and Myobloc for cervical dystonia and sialorrhea in adults. Its major pipeline products include SPN-830, SPN-812, SPN-817, and SPN-820. The company’s technology platforms include Microtrol (multi particulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). Supernus Pharmaceuticals is headquartered in Rockville, Maryland, the US.

The company reported revenues of (US Dollars) US$579.8 million for the fiscal year ended December 2021 (FY2021), an increase of 11.4% over FY2020. In FY2021, the company’s operating margin was 14.8%, compared to an operating margin of 33.4% in FY2020. In FY2021, the company recorded a net margin of 9.2%, compared to a net margin of 24.4% in FY2020. The company reported revenues of US$170.1 million for the second quarter ended June 2022, an increase of 11.5% over the previous quarter.

Quick View – Amantadine hydrochloride ER

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Amantadine hydrochloride ER
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Metabolic Disorders
  • Undisclosed
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.